Stock GLAND GLAND PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Gland Pharma Limited

Equities

GLAND

INE068V01023

Market Closed - NSE India S.E.
Other stock markets
 07:43:52 2024-05-13 am EDT 		5-day change 1st Jan Change
1,764 INR +3.18% Intraday chart for Gland Pharma Limited +4.62% -8.32%
May. 07 Gland Pharma Gets US FDA's Approval for Generic ALS Drug MT
May. 07 Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection MT

Evolution of the average Target Price on Gland Pharma Limited

Price target over the last 5 years

History of analyst recommendation changes

19748fba707040d1c11339116b.meizhzd2kwq56CwwjBCpG37LVJilQjIrzb-58pwilU8.9YDF4kUbp3yMulxn6VzAUUa_OKqIGFt9j-3jq-lI9wnvjvfuZwzGX4uZGA~064a99daa32d71ab6acb0edcae9f4be7

Analyst Recommendations on Gland Pharma Limited

Jefferies Adjusts Gland Pharma’s Price Target to INR2,400 From INR2,250, Keeps at Buy MT
Indian shares set to open lower as hot US inflation spurs rate worries RE
Nomura Upgrades Gland Pharma to Neutral From Reduce, Adjusts Price Target to INR1,570 From INR1,157 MT
Jefferies Adjusts Gland Pharma's Price Target to INR1,800 From INR1,640, Keeps at Buy MT
Indian shares set to open marginally higher RE
Nomura Downgrades Gland Pharma to Reduce From Neutral, Adjusts Price Target to INR1,157 From INR1,524 MT
Indian shares set for muted open ahead of GDP data RE
Nomura Adjusts Gland Pharma’s Price target to 2,236 Indian Rupees From 2,362 Rupees, Keeps at Neutral MT
Jefferies Downgrades Gland Pharma to Hold From Buy, Adjusts Price Target to 2,241 Indian Rupees From 2,843 Rupees MT
Nomura Adjusts Gland Pharma’s Price Target to 2,362 Indian Rupees From 3,809 Indian Rupees, Keeps at Neutral MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,710 INR
Average target price
1,845 INR
Spread / Average Target
+7.91%
High Price Target
3,120 INR
Spread / Highest target
+82.46%
Low Price Target
873 INR
Spread / Lowest Target
-48.95%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gland Pharma Limited

Nomura
Jefferies & Co.

Ratings for Gland Pharma Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GLAND Stock
  4. Consensus Gland Pharma Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW